Tivozanib in relapsed or refractory advanced renal cell carcinoma: a focus on US approval

Viray, H; McDermott, DF; Einstein, DJ

Viray, H (通讯作者),Harvard Med Sch, Beth Israel Deaconess Med Ctr, Div Med Oncol, 330 Brookline Ave, Boston, MA 02215 USA.

EXPERT REVIEW OF ANTICANCER THERAPY, 2022; 22 (7): 695

Abstract

Introduction Tivozanib is a selective vascular endothelial growth factor receptor (VEGFR)-inhibitor designed to, more specifically, bind to the VEGF r......

Full Text Link